- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
Patent holdings for IPC class C07D 401/04
Total number of patents in this class: 11562
10-year publication summary
945
|
839
|
907
|
882
|
901
|
881
|
877
|
827
|
810
|
205
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Bristol-myers Squibb Company | 5080 |
282 |
Novartis AG | 11238 |
218 |
Celgene Corporation | 1412 |
177 |
F. Hoffmann-La Roche AG | 7958 |
155 |
Merck Patent GmbH | 5909 |
155 |
Janssen Pharmaceutica N.V. | 3839 |
148 |
Boehringer Ingelheim International GmbH | 4629 |
147 |
Vertex Pharmaceuticals Incorporated | 1581 |
121 |
Takeda Pharmaceutical Company Limited | 2961 |
119 |
Merck Sharp & Dohme LLC | 3689 |
113 |
Hoffmann-La Roche Inc. | 3060 |
108 |
AstraZeneca AB | 3042 |
108 |
BASF SE | 19740 |
102 |
Syngenta Participations AG | 4970 |
100 |
Bayer AG | 3045 |
98 |
FMC Corporation | 910 |
98 |
Pfizer Inc. | 3322 |
93 |
Amgen Inc. | 3779 |
86 |
Sumitomo Chemical Company, Limited | 8808 |
84 |
Gilead Sciences, Inc. | 1879 |
79 |
Other owners | 8971 |